Platycodin D Inhibits Lipogenesis through AMPKα-PPARγ2 in 3T3-L1 Cells and Modulates Fat Accumulation in Obese Mice

Abstract

Platycodin D (PD) has been reported to control obesity in vivo. This study investigated the molecular mechanism of PD, focusing on its ability to decrease the expression of adipogenic factors through AMP-activated protein kinase α (AMPKα) in adipocytes and its ability to prevent abdominal fat accumulation in high-fat diet-induced obese C57BL/6 mice. The inhibitory effect of lipid accumulation in 3T3-L1 cells was measured by Oil Red O staining, reverse transcription-polymerase chain reaction (RT-PCR), and Western blotting. To determine the antiobesity effect in vivo, one group of mice were given a normal diet and the others were fed a high-fat diet for 8 weeks. The high-fat diet mice were then assigned to one of three subgroups: aminoimidazole carboxamide ribonucleotide (AICAR), vehicle, and PD. PD significantly reduced fat accumulation by inhibiting adipogenic signal transcriptional factors, such as peroxisome proliferator-activated receptor γ2 (PPARγ2) and CCAAT/enhancer binding protein α (C/EBPα), which functions via AMPK signaling, in vitro. PD reduced both body weight and fat volume; consequently, lipid metabolism was improved by increasing AMPKα, similar to AICAR, and reduced PPARγ2 and C/EBPα expression in adipose tissue. The results suggested that PD could be used to decrease the expression of adipogenic factors related to the AMPK pathway. Hence, PD could be an alternative treatment for controlling obesity by downregulating lipid accumulation.

Key words

abdominal obesity - adipocytes - adipogensis - platycodin D - Platycodon grandiflorum - Campanulaceae

• References

• 1 Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008; 94: 206-218
• 2 Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350
• 3 Frayn KN. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001; 60: 375-380
• 4 Rosen E, Eguchi J, Xu Z. Transcriptional targets in adipocyte biology. Expert Opin Ther Targets 2009; 13: 975-986
• 5 Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994; 79: 1147-1156
• 6 Uto-Kondo H, Ohmori R, Kiyose C. Tocotrienol suppresses adipocyte differentiation and Akt phosphorylation in 3T3-L1 preadipocytes. J Nutr 2009; 139: 51-57
• 7 Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007; 47: 185-210
• 8 Ha IJ, Ha YW, Kang M, Lee J, Park D, Kim YS. Enzymatic transformation of platycosides and one-step separation of platycodin D by high-speed countercurrent chromatography. J Sep Sci 2010; 33: 1916-1922
• 9 Zhao HL, Cho KH, Jeong TS, Ha YW, Lee SW, Kim YS. Cholesterol-lowering effect of platycodin D in hypercholesterolemic ICR mice. Eur J Pharm 2006; 537: 166-173
• 10 Han LK, Xu BJ, Kimura Y, Zheng Y, Okuda H. Platycodi radix affects lipid metabolism in mice with high fat diet-induced obesity. J Nutr 2000; 130: 2760-2764
• 11 Han LK, Zheng YN, Xu BJ, Okuda H, Kimura Y. Saponins from Platycodi radix ameliorate high fat diet-induced obesity in mice. J Nutr 2002; 132: 2241-2245
• 12 Lee H, Kang R, Kim YS, Chung SI, Yoon Y. Platycodin D inhibits adipogenesis of 3T3-L1 cells by modulating Kruppel-like factor 2 and peroxisome proliferator-activated receptor gamma. Phytother Res 2010; 24: 161-167
• 13 Ha YW, Kim YS. Preparative isolation of six major saponins from Platycodi Radix by high-speed counter-current chromatography. Phytochem Anal 2009; 20: 207-213
• 14 Waterborg JH, Matthews HR. The Lowry method for protein quantitation. Methods Mol Biol 1994; 32: 1-4
• 15 Fujioka K. Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options. Obes Res 2002; 10 (Suppl. 02) 116S-123S
• 16 Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288
• 17 Rosen E, Eguchi J, Xu Z. Transcriptional targets in adipocyte biology. Expert Opin Ther Targets 2009; 13: 975-986
• 18 Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006; 574: 63-71
• 19 Song XM, Fiedler M, Galuska JW, Fernstrom M, Chibalin AV, Wallberg-Henriksson H, Zierath JR. 5-Aminoimidazole-4-carboxamideribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 2002; 45: 56-65
• 20 Kim HG, Hien TT, Han EH, Chung YC, Jeong HG. Molecular mechanism of endothelial nitric-oxide synthase activation by Platycodon grandiflorum root-derived saponins. Toxicol Lett 2010; 195: 106-113
• 21 Kim SJ, Jung JY, Kim HW, Park T. Anti-obesity effects of Juniperus chinensis extract are associated with increased AMP-activated protein kinase expression and phosphorylation in the visceral adipose tissue of rats. Biol Pharm Bull 2008; 31: 1415-1421